Dividend compounder review
OGN
Organon & Co · NYSE · US
Healthcare · Drug Manufacturers - General
Score58.50/100
Confidence100.00/100
DecisionReject
RatingWeak Candidate
Quality breakdown
Dividend Reliability
9.0 / 25
Payment history, cuts, growth, and regularity.
Dividend Sustainability
17.0 / 20
Payout, free cash flow, dividend cover, and debt.
Business Quality
16.5 / 25
Scale, cash generation, growth, margins, and returns.
Valuation Discipline
11.0 / 15
Yield, P/E, and price stretch versus long-term trend.
Long-Term Trend
5.0 / 15
Trend line, long return history, and drawdown control.
Dividend and business context
Dividend Years5
Dividend Yield0.59%
Payout Ratio8.6%
Dividend Cut 5YYes
Net Income$187.0M
Free Cash Flow$384.0M
FCF Covers DividendYes
Debt / Equity9.49
P/E14.5
Revenue Growth 5Y-1.0%
Net Margin4.0%
ROE34.0%
Price vs Trend49.0%
3Y Return-24.6%
5Y Return-45.4%
CurrencyUSD
Review flags
Dividend cut or material annual decrease detected in the last five completed years.
Debt to equity is elevated at 9.49.
Activity record
Debt to equity is elevated at 9.49.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Payment changed from 0.28 to 0.02.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.
Recorded dividend payment for Organon & Co.